Financials

People

Activity

venBio Partners

Company

Investment-firm

Financing round

General

About Company
venBio is a life sciences investment firm that partners with industry leaders to develop groundbreaking medicines.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2009

Number of employees

IPO status

Private

Description

With a focus on the healthcare, oncology, life sciences, and HealthTech sectors, venBio invests in a wide range of companies, from seed-stage to later-stage, including academic startups and spinouts. They take a proactive approach, leading most of their investments and assembling syndicates and teams. venBio prioritizes the potential for acquisition partnerships, ensuring their portfolio companies are well-positioned to meet the requirements of potential buyers. By leveraging their team's expertise and involvement, venBio helps companies make a significant impact, fostering long-lasting relationships with industry leaders. Established in 2009, venBio is committed to driving innovation and growth in the life sciences industry.
Contacts

Contact Email

Social url

Similar Companies
133
GBS Ventures

GBS Ventures

GBS Venture Partners invests in innovative businesses improving patients' lives and generating returns.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Keywords

Biotechnology, Financial Services

Location

Dandenong Rd, Melbourne VIC, Australia

count Of Investments

60

count Of Exists

14
Hopen Life Science Ventures

Hopen Life Science Ventures

Hopen Life Science Ventures is a venture capital firm focused on life sciences.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Keywords

Biotechnology, Health Care, Venture Capital

Location

Grand Rapids, MI, USA

count Of Investments

12

count Of Exists

2
Pappas Capital

Pappas Capital

Pappas Capital invests in life science companies across the United States and Canada.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Location

Durham, NC, USA

count Of Investments

29

count Of Exists

3
Primer Capital

Primer Capital

Primer Capital is a venture capital firm in Moscow City that focuses on investing in biotech and medical companies.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Moscow, Russia

count Of Investments

14

Financials

Investments
71
Date 
name 
Lead 
type 
Raised 
Marea Therapeutics

Marea Therapeutics

Marea is a biotechnology firm that uses the advancements in human genetics next-generation medications for cardiometabolic illnesses.

total rounds

2

total raised

$190M
Attovia Therapeutics

Attovia Therapeutics

Attovia Therapeutics is developing biotherapeutics for immune-mediated diseases, with a particular focus on cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Pharmaceuticals

Location

Fremont, CA, USA

total rounds

2

total raised

$165M
Aeovian Pharmaceuticals

Aeovian Pharmaceuticals

Aeovian Pharmaceuticals develops innovative therapeutics for rare and age-related diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

San Francisco, CA, USA

total rounds

3

total raised

$87M
Co-Investors
Exits
5
Seragon Pharmaceuticals

Seragon Pharmaceuticals

Seragon Pharmaceuticals is a research-based biopharmaceutical company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Irvine, CA, USA

total rounds

1

total raised

$30M
Turning Point Therapeutics

Turning Point Therapeutics

Turning Point Therapeutics is developing investigational drugs to overcome limitations of existing cancer therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

San Diego, CA, USA

total rounds

8

total raised

$1.18B
Labrys Biologics

Labrys Biologics

Labrys Biologics Inc. is a company specialising in treatments for chronic migraine.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Francisco, CA, USA

total rounds

2

total raised

$45.59M

People

Founders
3
Robert Adelman
Robert Adelman

Robert Adelman

Robert J. Adelman, also known as Rob, M.D., is a co-founder of venBio LLC and serves as its Managing Director, Managing Partner and Partner. Robert Adelman has 30 year history of founding, investing in, and managing companies in the life sciences. Prior to that, Robert Adelman was a Partner at OrbiMed Advisors, L.L.C. At OrbiMed, he was part of a team that invested $1.1 billion in both public and private companies across three venture capital funds. Robert Adelman's focus was on private equity investments and structured transactions of small-capitalization public equity companies. Prior to joining OrbiMed, he served as the Vice President of Business Development at NeoGenesis Pharmaceuticals, Inc. Prior to his tenure with NeoGenesis, Robert Adelman founded Veritas Medicine, Inc. Robert Adelman co-founded Qiagen Operon, Inc. He has founded a number of biotechnology companies, including Sientra, Inc. and Roka Bioscience. As a Practicing Orthopedic Surgeon, he was involved with major implant manufacturers on hip and knee replacement design. Robert Adelman has been a Director of Innovative Spinal Technologies, Inc. since August 2, 2005. He serves as a Director of Precision BioSciences, Inc. since May 11, 2015. He has been a Director at HMBL Limited (formerly Heart Metabolics Limited) since April 2014. Robert Adelman has been an Independent Director at Seragon Pharmaceuticals Inc. since October 2012. He serves as a Director of ViewRay, Inc. and Solstice Biologics LLC. He served as a Member of the Board of Directors of Aragon Pharmaceuticals, Inc. and Sientra, Inc. Robert Adelman served as a Director of ARYx Therapeutics, Inc. from July 2002 to February 5, 2009 and CryoCor, Inc. from June 2003 to May 14, 2007. He served as an Independent Director at Volcano Corporation from February 2005 to June 7, 2007. He served as a Director of Cerimon Pharmaceuticals, Inc. He was trained as an Orthopedic Surgeon at the Hospital for Special Surgery at Cornell University. Robert Adelman received M.D. from Yale University School of Medicine and A.B. in Biochemistry with highest Honors from the University of California, Berkeley performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey.

current job

venBio Partners
venBio Partners

Robert Adelman

Corey Goodman
Corey Goodman

Corey Goodman

Corey Goodman is a renowned scientist, entrepreneur, educator, CEO, and corporate executive. Goodman is Founding Partner of venBio, Adjunct Professor at the University of California, San Francisco, and Chair of the Board of Directors of Limerick BioPharma, Second Genome, Oligasis, and Ossianix, and member of the Board of NeuroTherapeutics Pharma. He is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. Goodman was previously President of Pfizer's Biotherapeutics and Bioinnovation Center and a member of its Executive Leadership Team. He is a co-founder of Exelixis, Renovis, and Second Genome, and served as CEO of Renovis prior to its acquisition. Goodman is also a member of the California Council on Science and Technology, the Pacific Institute, the Board of the McKnight Endowment Fund for Neuroscience, BayBio, Biotechnology Institute, Bay Area Science and Innovation Consortium, New York Stem Cell Foundation, QB3 (UCSF-UCB-UCSC) Industry Advisory Board, Stanford's BioX Biosciences Advisory Council, Spinal Muscular Atrophy Foundation, and is former Chair of the National Research Council's Board on Life Sciences. During his academic career, Goodman spent over two decades as a professor of biology and neuroscience at Stanford and U.C. Berkeley, and earning numerous scientific awards such as the Alan T. Waterman Award from the National Science Board, the Gairdner International Award for Achievement in Medical Sciences, and the March-of-Dimes Prize in Developmental Biology. Goodman received his B.S. from Stanford University, Ph.D. from U.C. Berkeley, and was a postdoctoral fellow at U.C. San Diego.

current job

Labrys Biologics
Labrys Biologics

count Of Investments

2

Corey Goodman

Kurt von Emster
Kurt von Emster

Kurt von Emster

current job

Abingworth
Abingworth

Kurt von Emster

Employee Profiles
9
Aaron Royston

Aaron Royston

Partner

Richard Gaster

Richard Gaster

Partner

Robert Adelman

Robert Adelman

Investment Manager

Kurt von Emster

Kurt von Emster

Co - Founder & Managing Partner

Behzad Aghazadeh

Behzad Aghazadeh

Managing Team

Paul Brooke

Paul Brooke

Managing Team

John Borgeson

John Borgeson

CFO

Corey Goodman

Corey Goodman

Founding Partner

Activity

Recent News
12
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week